Steroid-responsive inclusion body myositis associated with endometrial cancer

Doru T. Alexandrescu, Niyati S. Bhagwati, Barry Fomberstein, David E. Wolfe, Aaron Feliz, Peter H. Wiernik

Research output: Contribution to journalArticle

9 Scopus citations

Abstract

Inclusion body myositis (IBM) is an uncommon chronic inflammatory myopathy. Although the association between other myopathies and cancer has been well established, the relationship between IBM and neoplasia is not completely understood. Unlike polymyositis (PM) or dermatomyositis (DM), IBM rarely responds to immunosuppressive treatment and the response is seldom long-lasting. We describe a case of IBM associated with endometrial carcinoma that also demonstrated a unique response to steroids alone which persisted despite cancer relapse. The factors that are associated with a response of IBM to steroids are discussed. An atypical, steroid-responsive form of the disease is delineated.

Original languageEnglish (US)
Pages (from-to)93-96
Number of pages4
JournalClinical and Experimental Rheumatology
Volume23
Issue number1
StatePublished - Jan 1 2005

Keywords

  • Atypical
  • Endometrial carcinoma
  • Inclusion body myositis
  • Steroids

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'Steroid-responsive inclusion body myositis associated with endometrial cancer'. Together they form a unique fingerprint.

  • Cite this

    Alexandrescu, D. T., Bhagwati, N. S., Fomberstein, B., Wolfe, D. E., Feliz, A., & Wiernik, P. H. (2005). Steroid-responsive inclusion body myositis associated with endometrial cancer. Clinical and Experimental Rheumatology, 23(1), 93-96.